JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

Strona główna・Stock List・AnaptysBio Inc

AnaptysBio Inc

Closed

SectorHealthcare

66.53 1.43

Buy Sell

Overview

Share price change

24h

Current

Min

66.04

Max

66.96

Key metrics
By Trading Economics
Income	35M 50M
Sales	32M 108M
Profit margin	45.833
Employees	104
EBITDA	29M 68M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+12.17% upside

Dividends
By Dow Jones
Next Earnings	8 maj 2026

Market Stats
By TradingEconomics
Market Cap	495M 2B
Previous open	65.1
Previous close	66.53

News Sentiment

By Acuity

13%

87%

14 / 347 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Strong Bearish Evidence

19.25 / 21.135 Support & Resistance

AnaptysBio Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

5 maj 2026, 23:43 UTC

Major News Events

New Zealand's Unemployment Rate Falls in 1Q

5 maj 2026, 23:20 UTC

Hot Stocks

Stocks to Watch: AMD, Super Micro, Arista Networks, Freshworks

5 maj 2026, 21:48 UTC

Earnings

Suncor Energy Reports Higher 1Q Profit on Increased Oil Production

5 maj 2026, 21:05 UTC

Acquisitions, Mergers, Takeovers

Canada Antitrust Watchdog Seeks to Kibosh Keyera Deal for Plains' Canada Gas Business -- 4th Update

6 maj 2026, 00:00 UTC

Market Talk

Canada Energy Minister Signals Energy Investments in the Pipeline -- Market Talk

5 maj 2026, 23:39 UTC

Market Talk

Gold Rises; Trump Pauses 'Project Freedom' to See if Iran Deal Can Be Finalized -- Market Talk

5 maj 2026, 22:26 UTC

Market Talk

AMD Data-Center Business Continues to Surge -- Market Talk

5 maj 2026, 22:20 UTC

Market Talk

AMD's AI Revolution is Still in Early Innings, Analysts Say -- Market Talk

5 maj 2026, 22:08 UTC

Earnings

Correction to "Palantir Beats Forecasts" on May 4. -- WSJ

5 maj 2026, 22:07 UTC

Earnings

AMD Stock Soars on Strong Earnings and Growing Confidence About AI -- Barrons.com

5 maj 2026, 21:48 UTC

Earnings

Pan American Silver 1Q Adj EPS $1.09 >PAAS

5 maj 2026, 21:48 UTC

Earnings

Pan American Silver 1Q Rev $1.2B >PAAS

5 maj 2026, 21:42 UTC

Earnings

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

5 maj 2026, 21:38 UTC

Earnings

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

5 maj 2026, 21:30 UTC

Earnings

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

5 maj 2026, 21:29 UTC

Earnings

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

5 maj 2026, 21:26 UTC

Earnings

Strategy Posts Wider Loss as Bitcoin Holdings Hit $64 Billion. The Stock Falls. -- Barrons.com

5 maj 2026, 21:25 UTC

Earnings

Alcon Inc. 1Q EPS 39c >ALC.EB

5 maj 2026, 21:25 UTC

Earnings

Alcon Inc. 1Q Rev $2.71B >ALC.EB

5 maj 2026, 21:24 UTC

Earnings

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

5 maj 2026, 21:18 UTC

Earnings

Mistras Backs 2026 Rev $730M-$750M >MG

5 maj 2026, 21:17 UTC

Earnings

AMD Stock Jumps on Solid Earnings. AI Continues to Drive Data Center Chips. -- Barrons.com

5 maj 2026, 21:15 UTC

Earnings

Strategy Records Loss of Nearly $13 Billion as Bitcoin Continues Decline -- WSJ

5 maj 2026, 21:12 UTC

Earnings

These Stocks Are Today's Movers: Intel, PayPal, Palantir, Shopify, Micron, Duolingo, and More -- Barrons.com

5 maj 2026, 21:11 UTC

Earnings

SSR Mining 1Q Rev $581.8M >SSRM

5 maj 2026, 21:10 UTC

Earnings

SSR Mining 1Q Adj EPS $1.15 >SSRM

5 maj 2026, 21:10 UTC

Earnings

SSR Mining 1Q EPS $1.16 >SSRM

5 maj 2026, 21:08 UTC

Earnings

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

5 maj 2026, 21:01 UTC

Earnings

Intact Financial 1Q EPS C$4.12 >IFC.T

5 maj 2026, 21:01 UTC

Hot Stocks

Stocks to Watch Recap: Palantir, AMD, Intel, HSBC -- WSJ

Peer Comparison

Price change

AnaptysBio Inc Forecast

Price Target

By TipRanks

12.17% upside

12 Months Forecast

Average 78.27 USD 12.17%

High 140 USD

Low 50 USD

Based on 11 Wall Street analysts offering 12 month price targets forAnaptysBio Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

11 ratings

Buy

Hold

Sell

Based on 11 analysts giving stock ratings to AnaptysBio Inc - Dist in the past 3 months.

Technical Score

By Trading Central

19.25 / 21.135Support & Resistance

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

14 / 347 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About AnaptysBio Inc

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.